Latest Breaking News On - Research at retina consultants of texas - Page 1 : comparemela.com

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFred guerardFrederic guerardKelleherlifesci advisorsemailRudi michelsonmonsoon communicationstelCharlesc wykoffResearch at retina consultants of texasExchange commissionCompany media enquiriesRegeneron pharmaceuticals incRoche groupOpthea limitedInvestment in biotechnology companiesGenentech united states incAge related macular degenerationChief executive officer

EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting

EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesPalm springsCity ofDavidr guyerTony adamisCharlesc wykoffDavid guyerMatt peraMerck co incResearch at retina consultants of texasClinical trials committeeVentures fundSv health investorsMacula society meeting in palmEyebiotech limited eyebio

Regeneron (REGN) Presents Results from Two-year Results from Pivotal PULSAR Trial of EYLEA HD

Regeneron (REGN) Presents Results from Two-year Results from Pivotal PULSAR Trial of EYLEA HD
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCharlesc wykoffAmerican society of retina specialistsResearch at retina consultants of texasBayer agRegeneron pharmaceuticals incRegeneron pharmaceuticalsRetina consultantsAmerican societyRetina specialists

Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration

88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the end of two years 78% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals throughout the two-year. -Today at 07:03 am- MarketScreener

United statesMark hudsonMary heatherCharlesc wykoffGeorged yancopoulosBayer agClinical trial programAmerican society of retina specialistsRegeneron genetics centerRegeneron pharmaceuticals incExchange commissionResearch at retina consultants of texasRetina consultantsChief scientific officerAmerican societyRetina specialists

RetinAI and Retina Consultants of America Join Forces

The partnership aims to build the most comprehensive U.S.-based real world evidence database in ophthalmology.

United statesNew yorkSouth dakotaSouth carolinaNorth carolinaDavidm brownCharles wykoffCarlos cillerClinical trials committeeResearch at retina consultants of texasRetina consultantsReal world evidenceAge related macular degenerationGeographic atrophyDiabetic macular edemaDiabetic retinopathy